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Rare Mutations in XRCC2 Increase
the Risk of Breast Cancer
D.J. Park,1,20 F. Lesueur,2,20 T. Nguyen-Dumont,1 M. Pertesi,2 F. Odefrey,1 F. Hammet,1 S.L. Neuhausen,3
E.M. John,4,5 I.L. Andrulis,6 M.B. Terry,7 M. Daly,8 S. Buys,9 F. Le Calvez-Kelm,2 A. Lonie,10 B.J. Pope,10
H. Tsimiklis,1 C. Voegele,2 F.M. Hilbers,11 N. Hoogerbrugge,12 A. Barroso,13 A. Osorio,13,14 the Breast
Cancer Family Registry, the Kathleen Cuningham Foundation Consortium for Research into Familial
Breast Cancer, G.G. Giles,15 P. Devilee,11,16 J. Benitez,13,14 J.L. Hopper,17 S.V. Tavtigian,18 D.E. Goldgar,19
and M.C. Southey1,*
An exome-sequencing study of families with multiple breast-cancer-affected individuals identified two families with XRCC2mutations,
one with a protein-truncatingmutation and one with a probably deleterious missensemutation.We performed a population-based case-
control mutation-screening study that identified six probably pathogenic coding variants in 1,308 cases with early-onset breast cancer
and no variants in 1,120 controls (the severity grading was p< 0.02). We also performed additional mutation screening in 689 multiple-
case families. We identified ten breast-cancer-affected families with protein-truncating or probably deleterious rare missense variants in
XRCC2. Our identification of XRCC2 as a breast cancer susceptibility gene thus increases the proportion of breast cancers that are asso-
ciated with homologous recombination-DNA-repair dysfunction and Fanconi anemia and could therefore benefit from specific targeted
treatments such as PARP (poly ADP ribose polymerase) inhibitors. This study demonstrates the power of massively parallel sequencing
for discovering susceptibility genes for common, complex diseases.Currently, only approximately 30% of the familial risk for
breast cancer has been explained, leaving the substantial
majority unaccounted for.1 Recently, exome sequencing
has been demonstrated to be a powerful tool for identi-
fying the underlying cause of rare Mendelian disorders.
However, diseases such as breast cancer present substan-
tially increased complexity in terms of locus, allelic and
phenotypic heterogeneity, and relationships between
genotype and phenotype.
As part of a collaborative (Leiden University Medical
Centre, the Spanish National Cancer Center, and The
University of Melbourne) project involving the exome
capture and massively parallel sequencing of multiple-
case breast-cancer-affected families, we applied whole-
exome sequencing to DNA frommultiple affected relatives
from 13 families (family structure and sample availability
were considered before the affected relatives were chosen).
Bioinformatic analysis of the resulting exome sequences
identified a protein-truncating mutation, c.651_652del
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blood DNA of a man participating in the Australian Breast
Cancer Family Registry2 (ABCFR; Figure 1A); this man (III-4
in Figure 1A) had been diagnosed with breast cancer at
29 years of age, and his mother (II-3), sister (III-5), and
cousin (III-1) had been diagnosed with breast cancer at
37, 41, and 34 years of age, respectively. The cousin
(III-1), who had also been selected for exome sequencing,
did not carry this mutation, the sister’s DNA was Sanger
sequenced and was found to carry the mutation, and there
was no DNA available for testing of the mother. Exome
sequencing of three individuals from a family participating
in a Dutch research study of multiple-case breast-cancer-
affected families identified a probably deleterious missense
mutation (c.271C>T [p.Arg91Trp] in XRCC2) (Figure 2) in
two sisters (II-6 and II-8 in Figure 1B) diagnosed with breast
cancer at 40 and 48 years of age, respectively, but not in
their cousin (II-1), who was diagnosed at 47 years of age.
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Figure 1. Pedigrees of Families Found to Carry XRCC2 Mutations
Mutation status is indicated for all family members for whom a DNA sample was available. Cancer diagnosis and age of onset are indi-
cated for affected members. Asterisks indicate that DNA underwent exome sequencing (libraries for 50 bp fragment reads were prepared
according to the SOLiD Baylor protocol 2.1 and the Nimblegen exome-capture protocol v.1.2 with some variations). The following
abbreviations are used: BC, breast cancer (black filled symbols); PC, pancreatic cancer; BwC, bowel cancer; UC, uterine cancer; MM,
malignant melanoma; UK, unknown age; BlC, bladder cancer; OC, ovarian cancer; BCC, basal cell carcinoma; L, lung cancer; (all
gray-filled symbols); V, verified cancer (via cancer registry or pathology report); and wt, wild-type. Some symbols represent more than
one person as indicated by a numeral.and 1,436 controls from the Melbourne Collaborative
Cohort Study3 (MCCS) and the ABCFR revealed one
control (II-2, Figure 1C) who carried c.651_652del
(p.Cys217*). Intriguingly, this control individual’s sister
(II-1) was diagnosed with breast cancer at 63 years of age,
and her mother (I-2) was diagnosed with melanoma at
69 years of age (Figure 1C, Tables 1 and 2).
XRCC2, a RAD51 paralog, was cloned because of its
ability to complement the DNA-damage sensitivity of the
irs1 hamster cell line.4 Cells derived from Xrcc2-knockout
mice exhibit profound genetic instability as a result of
homologous recombination (HR) deficiency.5 XRCC2 is
highly conserved, and most truncations of the protein
destroy its ability to protect cells from the effects of the
DNA cross-linking agent mitomycin C.6 The involvement
of the HR DNA repair genes BRCA1 (MIM 113705),
BRCA2 (MIM 600185), ATM (MIM 607585), CHEK2 (MIM
604373), BRIP1 (MIM 605882), PALB2 (MIM 610355),
and RAD51C (MIM 602774) in breast cancer risk empha-
sizes the importance of this mechanism in the etiology
of breast cancer.7–9 Biallelic mutations in three of these
genes are associated with Fanconi anemia (FA), and, mostThe Aminterestingly, Shamseldin et al.10 have recently reported
a homozygous frameshift mutation in XRCC2 as being
associated with a previously unrecognized form of FA.
XRCC2 binds directly to the C-terminal portion of the
product of the breast cancer susceptibility pathway gene
RAD51 (MIM 179617), which is central to HR.6,11 XRCC2
also complexes in vivo with RAD51B (RAD51L1 [MIM
602948]), the product of the breast and ovarian cancer
susceptibility gene RAD51C9 and the product of the
ovarian cancer risk gene RAD51D (MIM 602954),12,13 and
localizes to sites of DNA damage.6 Cells deficient in
XRCC2 also show centrosome disruption, a key compo-
nent of mitotic-apparatus dysfunction, which is often
linked to the onset of mitotic catastrophe. XRCC2 is
important in preventing chromosome missegregation
leading to aneuploidy.14 Studies of common genetic varia-
tion in XRCC2 have reported some evidence of association
with breast cancer risk (e.g., rs3218408),15 subtle effects on
DNA-repair capacity,16 and poor survival associated with
rs3218536 (XRCC2, Arg188His).15
On the basis of the exome-sequencing results, the subse-
quent genotyping of the two probably pathogenic variantserican Journal of Human Genetics 90, 734–739, April 6, 2012 735
Figure 2. XRCC2 Multiple-Sequence Alignment Centered on
Position Arg91
Missense substitutions observed in this interval are given with the
missense residue directly above the corresponding human refer-
ence sequence residue. The following abbreviations are used:
Hsap, Homo sapiens; Mmul,Macaca mulatta; Mmus,Mus musculus;
Cfam,Canis familiaris; Lafr,Loxodonta africana;Mdom,Monodelphis
domestica; Oana, Ornithorhynchus anatinus; Ggal, Gallus gallus;
Acar, Anolis coralinensis; Xtro, Xenopus tropicalis; Drer, Danio rerio;
Bflo, Branchiostoma floridae; Spur, Strongylocentrotus purpuratus;
Nvec, Nematostella vectensis; and Tadh, Trichoplax adhaerans. The
alignment, or updated versions thereof, is available at the Align-
GVGD website (see Web Resources).in the MCCS and ABCFR, the rarity of these variants, and
the biochemical plausibility of XRCC2, we conducted two
further studies in parallel. The first study was case-control
mutation screening of XRCC2 (with high-resolution melt
[HRM] curve analysis followed by Sanger-sequencing
confirmation) in an additional series of 1,308 cases with
early-onset breast cancer and 1,120 frequency-matched
controls recruited through population-based sampling
by the Breast Cancer Family Registry2 (BCFR; Supplemental
Data, available online); the BCFR sampling was recently
carried out for the characterization of the breast cancer
risk associated with variants in ATM and CHEK2.17,18 The
second study was mutation screening of XRCC2 in a series
of index cases from multiple-case breast-cancer-affected
families and a series of male breast cancer cases.
The case-control mutation screening identified two cases
that carried protein-truncating variants in XRCC2: indi-
vidual III-2 had c.49C>T (p.Arg17*) (Figure 1F), and indi-
vidual II-1 had c.651_652del (p.Cys217*) (Figure 1G).
Five cases carried singleton missense substitutions ranging
from probably deleterious to relatively innocuous (accord-
ing to in silico prediction). One control carried a relatively
innocuous missense substitution (Table 2). In addition,
a case diagnosed with breast cancer at 32 years of age
carried a G>A substitution located one nucleotide prior
to the start codon.
We graded the rare missense variants by using three
computational tools: SIFT, Polyphen2.1, and Align-
GVGD. Differences in grading between these tools were
minor. Depending on which of the three computational
tools we used to grade the missense substitutions, the736 The American Journal of Human Genetics 90, 734–739, April 6, 2statistical significances of the differences in the frequency
and severity distributions of protein-truncating variants
and rare missense substitutions between cases and controls
from the case-control mutation-screening study fell in the
range of p¼ 0.01–0.02 (adjusted for race, study center, and
age). There were six probably deleterious variants (pre-
dicted deleterious by at least two prediction algorithms)
in the cases and none in the controls, corresponding to
a p value by Fisher’s exact test of 0.02. All together, the
case-control mutation-screening data provide statistical
support for the hypothesis that rare, evolutionarily
unlikely sequence variation in XRCC2 is associated with
increased risk of breast cancer.
Mutation screening (by Sanger sequencing) of XRCC2 in
the index cases of 689 multiple-case breast-cancer-affected
families participating in the BCFR and the Kathleen
Cuningham Foundation Consortium for Research into
Familial Breast Cancer19 (kConFab) plus 150 male breast
cancer cases participating in a US-based study of male
breast cancer (Beckman Research Institute of the City of
Hope20) and kConFab revealed three rare coding-sequence
alterations. We identified a second family (from the kCon-
Fab resource) with an index case who carried XRCC2
c.651_652del (p.Cys217*); this individual (II-5, Figure 1D)
also carried a truncating mutation in BRCA1 (c.70_80del
[p.Cys24Serfs*13]). We identified an ABCFR index case
(II-2, Figure 1E and Figure 2) who carried the previously
identified missense substitution, XRCC2 c.271C>T
(p.Arg91Trp). We also identified a male breast cancer case
who carried a relatively innocuous missense substitution,
c.283A>C (p.Ile95Leu).
In addition to the protein-truncating mutations and the
above-described missense variants, a number of missense,
silent, and intronic variants were also observed in
XRCC2, and common SNPs that were reported in public
databases such as dbSNP, HapMap, or the 1,000 Genomes
Project were also identified. These included the common
coding SNP c.563G>A (p.Arg188His) (rs3218536), one
silent substitution, three 50UTR variants, five 30UTR vari-
ants, and six intronic variants in the vicinity of exon-
intron boundaries. All these variants were predicted to be
neutral according to various in silico predictions tools
(Supplemental Data, Tables 1 and 2). For common SNPs
(>1% in controls), no difference in allele frequency was
observed between cases and controls in the BCFR series.
The genetic studies included in this report received ap-
proval from The University of Melbourne Human Research
Ethics Committee, the International Agency for Research
on Cancer institutional review board (IRB), and the local
IRBs of every center from which we report findings.
Of the six distinct rare variants predicted to severely
affect protein function and identified in ourwork, twowere
truncating mutations, and four were missense changes.
Although most recognized pathogenic mutations in the
major breast cancer susceptibility genes are protein trun-
cating, there is evidence that missense mutations might
be the more prominent of some more recently-identified012
Table 1. Mutation Screening in Multiple-Case Breast Cancer Families
Rare XRCC2 Variants
Effect on
Protein Align-GVGDa SIFTb
PolyPhen-2.1
(HumDiv)
Case or
Control
Pedigree
(Study Source)
Age and Origin
of Carrier
Truncating variants
c.651_652del p.Cys217*    case Figure 1A (ABCFR)e 29, white
c.651_652del p.Cys217*    casec Figure 1C (kConFab) 36, white
c.651_652del p.Cys217*    control Figure 1D (MCCS) 72, white
Missense substitutions
c.271C>T p.Arg91Trp C65 0.00 probably damaging case Figure 1B (Dutch)e 40, white
c.271C>T p.Arg91Trp C65 0.00 probably damaging cased Figure 1E (ABCFR) 32, white
c.283A>C p.Ile95Val C0 0.34 benign case  (kConFab) 59, white
c.283A>G p.Ile95Leu C0 0.41 benign case  (kConFab) 70, white
c.283A>C p.Ile95Val C0 0.34 benign case  (BRICOH) 68, white
Silent substitution
c.582G>T p.Thr194Thr    case  (kConFab) 60, white
The following abbreviations are used: ABCFR; Australian Breast Cancer Family Registry; kConFab, Kathleen Cuningham Foundation Consortium for Research into
Familial Breast Cancer; MCCS, Melbourne Collaborative Cohort Study; and BRICOH, Beckman Research Institute of City of Hope.
aProtein multiple sequence alignment (PMSA) used for obtaining scores for Align-GVGD: from Human to Branchiostoma floridae (Bflo).
bPMSA used for obtaining scores for SIFT: from Human to Trichoplax (Tadh).
cThis woman also carries BRCA1 c.70_80del (p.Cys24Serfs*13).
dThis carrier of p.Arg91Trp was identified through both the ABFCR multiple-case family screening and the BCFR-IARC (Breast Cancer Family Registry-International
Agency for Research on Cancer) case-control screening.
eFamily included in the exome-sequencing phase.breast cancer susceptibility genes. For example, in compre-
hensive studies ofATM andCHEK2, the proportion of prob-
ably deleterious or pathogenic rare sequence variants that
are missense changes is often over 50%. More relevantly,
estimates of breast cancer risk are higher for missense vari-
ants than they are for protein-truncating variants. This
has been observed through case-control mutation-
screening analyses of ATM and CHEK217,18 and through
a pedigree analysis21 of ATM; in these analyses, the breast
cancer risk associated with one specific missense mutation
approaches the average risk associated with pathogenic
BRCA2 mutations. A very recent analysis of PALB2 muta-
tions found no difference in the frequency of missense
mutations between two case groups (contralateral and
unilateral breast cancer cases),22 suggesting that the contri-
bution of missense mutations to breast cancer risk might
vary between susceptibility genes.
Our finding of XRCC2 as a breast cancer susceptibility
gene expands the proportion of breast cancer that is associ-
ated with rare mutations in the HR-DNA-repair pathways
and the number of breast cancer susceptibility genes in
whichbiallelicmutations are associatedwith FA; theprecise
contribution ofmutation in these geneswill become clearer
as more whole-exome-sequencing (or whole-genome-
sequencing) and targeted-pathway-sequencing studies are
performed. XRCC2 mutations appear to be very rare, even
in the context of multiple-case families; they appear in 1
of 66 (1.5%) early-onset female breast cancer cases with
a strong family history of the disease present in the ABCFR,
compared to 9 (14%) BRCA1 mutations, 6 (9%) BRCA2The Ammutations, 3 (5%) TP53 (MIM 191170) mutations, and 2
(3%) PALB2mutations.
These frequencies are consistent with data from both
breast cancer linkage studies that have suggested that no
single gene is likely to account for a large fraction of the re-
maining familial aggregation of breast cancer5 and reports
from recent candidate-gene sequencing studies that have
associated other members of the HR pathway with breast
cancer susceptibility.23,24 Although mutations in HR-
DNA-repair genes are rare, it is important to identify people
whose breast cancer is associated with HR-DNA-repair
dysfunction because they could benefit from specific tar-
geted treatments such as PARP inhibitors. Unaffected rela-
tives of people with a mutation in a HR-DNA-repair gene
could also be offered predictive testing and subsequent
clinical management and genetic counseling on the basis
of their mutation status. The identification of a family
with rare mutations in both XRCC2 and BRCA1 illustrates
the complexity of the underlying genetic architecture of
breast cancer susceptibility for some families and the chal-
lenges for personalized risk-prediction models that are
incorporating an increasing array of risk factors, which
include rare mutations in breast cancer susceptibility genes
and more common genetic variation. Currently, esti-
mating the relative importance of the XRCC2 mutation
to the breast cancer risk for members of this family is diffi-
cult because of the presence of a BRCA1 protein-truncating
mutation in the proband in addition to the XRCC2 muta-
tion. Many examples have been described of individuals
and families carrying deleterious mutations in more thanerican Journal of Human Genetics 90, 734–739, April 6, 2012 737
Table 2. Case-Control Mutation Screening Applied to the BCFR Population-Based Study
Rare XRCC2 Variants
Effect on
Protein Align-GVGDa SIFTb
PolyPhen-2.1
(HumDiv)
Case (n ¼ 1,308) or
Control (n ¼ 1,120)
Pedigree
(BCFR)
Age and Origin
of Carrier
Truncating variants
c.49C>T p.Arg17*    case Figure 1F 33, white
c.46G>T p.Ala16Ser C0 0.24 benign case  44, East Asian
c.181C>A p.Leu61Ile C0 0.00 possibly damaging case Figure 1H 30, East Asian
c.271C>T p.Arg91Trp C65 0.00 probably damaging casec Figure 1E 32, white
c.283A>G p.Ile95Val C0 0.34 benign control  44, white
c.693G>T p.Trp231Cys C65 0.00 probably damaging cased Figure 1I 44, East Asian
c.808T>G p.Phe270Val C45 0.00 probably damaging case Figure 1J 38, African
Silent substitution
c.354G>A p.Val118Val    cased  44, East Asian
50 UTR variants
c.-1G>A ?    casee  32, white
The following abbreviation is used: BCFR, Breast Cancer Family Registry.
aProtein multiple sequence alignment (PMSA) used for obtaining scores for Align-GVGD: from Human to Branchiostoma floridae (Bflo).
bPMSA used for obtaining scores for SIFT: from Human to Trichoplax (Tadh).
cThis carrier of p.Arg91Trp was identified through both the ABFCR multiple-case family screening and the BCFR-IARC (Breast Cancer Family Registry-International
Agency for Research on Cancer) case-control screening.
dThis 44-year-old East Asian case carries p.Trp231Cys and p.Val118Val.
eThis case is considered a ‘‘noncarrier’’ in the analysis.one proven breast cancer susceptibility gene; one such
example is the co-observation of BRCA1, BRCA2, ATM,
and CHEK2 mutations.21,25
This study demonstrates the power of massively parallel
sequencing in the discovery of additional breast cancer
susceptibility genes when used with an appropriate study
design. Our approach could be applied to other common,
complex diseases with components of unexplained herita-
bility.Supplemental Data
Supplemental Data include 6 tables and can be found with this
article online at http://www.cell.com/AJHG.Acknowledgments
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The URLs for data presented herein are as follows:
Align-GVGD, http://agvgd.iarc.fr/alignments
GATK v.1.0.4418, http://gatk.sourceforge.net/
Genome Viewer (IGV v.1.5.48), http://www.broadinstitute.org/
software/igv/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
Picard v.1.29, http://sourceforge.net/projects/picard/
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SIFT, http://sift.jcvi.org/
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